100 related articles for article (PubMed ID: 26759243)
1. Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response.
Conery AR; Centore RC; Spillane KL; Follmer NE; Bommi-Reddy A; Hatton C; Bryant BM; Greninger P; Amzallag A; Benes CH; Mertz JA; Sims RJ
Cancer Res; 2016 Mar; 76(6):1313-9. PubMed ID: 26759243
[TBL] [Abstract][Full Text] [Related]
2. BET bromodomain inhibitors synergize with ATR inhibitors in melanoma.
Muralidharan SV; Einarsdottir BO; Bhadury J; Lindberg MF; Wu J; Campeau E; Bagge RO; Stierner U; Ny L; Nilsson LM; Nilsson JA
Cell Death Dis; 2017 Aug; 8(8):e2982. PubMed ID: 28796244
[TBL] [Abstract][Full Text] [Related]
3. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
Gayle SS; Sahni JM; Webb BM; Weber-Bonk KL; Shively MS; Spina R; Bar EE; Summers MK; Keri RA
J Biol Chem; 2019 Jan; 294(3):875-886. PubMed ID: 30482844
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
Ambrosini G; Do C; Tycko B; Realubit RB; Karan C; Musi E; Carvajal RD; Chua V; Aplin AE; Schwartz GK
Cancer Res; 2019 May; 79(9):2415-2425. PubMed ID: 30885979
[TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.
Muralidharan SV; Bhadury J; Nilsson LM; Green LC; McLure KG; Nilsson JA
Oncogene; 2016 Sep; 35(36):4689-97. PubMed ID: 26804177
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies.
Lasorsa E; Smonksey M; Kirk JS; Rosario S; Hernandez-Ilizaliturri FJ; Ellis L
Cell Death Dis; 2015 Dec; 6(12):e2014. PubMed ID: 26658189
[TBL] [Abstract][Full Text] [Related]
7. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.
Kurimchak AM; Shelton C; Duncan KE; Johnson KJ; Brown J; O'Brien S; Gabbasov R; Fink LS; Li Y; Lounsbury N; Abou-Gharbia M; Childers WE; Connolly DC; Chernoff J; Peterson JR; Duncan JS
Cell Rep; 2016 Aug; 16(5):1273-1286. PubMed ID: 27452461
[TBL] [Abstract][Full Text] [Related]
8. Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.
Romine KA; Nechiporuk T; Bottomly D; Jeng S; McWeeney SK; Kaempf A; Corces MR; Majeti R; Tyner JW
Blood Cancer Discov; 2021 Sep; 2(5):518-531. PubMed ID: 34568834
[TBL] [Abstract][Full Text] [Related]
9. Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression.
Changchien JJ; Chen YJ; Huang CH; Cheng TL; Lin SR; Chang LS
Toxicol Appl Pharmacol; 2015 Apr; 284(1):33-41. PubMed ID: 25684043
[TBL] [Abstract][Full Text] [Related]
10. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
11. Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.
Fontanals-Cirera B; Hasson D; Vardabasso C; Di Micco R; Agrawal P; Chowdhury A; Gantz M; de Pablos-Aragoneses A; Morgenstern A; Wu P; Filipescu D; Valle-Garcia D; Darvishian F; Roe JS; Davies MA; Vakoc CR; Hernando E; Bernstein E
Mol Cell; 2017 Nov; 68(4):731-744.e9. PubMed ID: 29149598
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and cytotoxic evaluation of novel N-substituted amidino-1-hydroxybenzimidazole derivatives.
Alp M; Göker H; Ozkan T; Sunguroglu A
Arch Pharm Res; 2014 May; 37(5):580-7. PubMed ID: 23835831
[TBL] [Abstract][Full Text] [Related]
13. Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non-Small Cell Lung Cancer Cells.
Sun L; Wu Q; Huan XJ; Tian CQ; Wang YQ; Miao ZH
Mol Cancer Res; 2022 Dec; 20(12):1785-1798. PubMed ID: 36001806
[TBL] [Abstract][Full Text] [Related]
14. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
[TBL] [Abstract][Full Text] [Related]
15. The novel synthesized 2-(3-(methylamino)phenyl)-6-(pyrrolidin-1-yl)quinolin-4-one (Smh-3) compound induces G2/M phase arrest and mitochondrial-dependent apoptotic cell death through inhibition of CDK1 and AKT activity in HL-60 human leukemia cells.
Huang SM; Yang JS; Tsai SC; Chen MH; Hsu MH; Lin HY; Chou LC; Chinag JH; Lee KH; Huang LJ; Kuo SC
Int J Oncol; 2011 May; 38(5):1357-64. PubMed ID: 21344160
[TBL] [Abstract][Full Text] [Related]
16. Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells.
AbuSara N; Razavi S; Derwish L; Komatsu Y; Licursi M; Hirasawa K
Cancer Lett; 2015 Feb; 357(2):575-81. PubMed ID: 25497010
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways.
Meng J; Zhang HH; Zhou CX; Li C; Zhang F; Mei QB
Oncol Rep; 2012 Jul; 28(1):384-8. PubMed ID: 22552631
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
19. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
20. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Scarfò L; Ghia P
Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
